a public good project by the
Synthesis
Company
of California

© 2026

Martine P. Roudier | doi.page

0 works0 citations0 h-index

Martine P. Roudier

University of Washington(US)Fred Hutch Cancer Center(US)Seattle University(US)

Publications by Year

Research Areas

Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Bone health and treatments, Melanoma and MAPK Pathways, PI3K/AKT/mTOR signaling in cancer

Most-Cited Works

→ Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study(2010)705 cited
→ Genomic and phenotypic heterogeneity in prostate cancer(2020)489 cited
→ Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone(2003)308 cited
→ LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics(2017)307 cited
→ The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models(2018)302 cited
→ Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling(2021)293 cited

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

(2003)

→ Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis(2007)209 cited

→ Establishment and characterization of osseous prostate cancer models: Intra‐tibial injection of human prostate cancer cells(2002)192 cited

→ SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer(2015)178 cited